Relapsed Plasmablastic Lymphoma in a HIV negative patient: pushing the envelope

Abstract

We report a case of Plasmablastic Lymphoma occurring in a 45-year-old HIV-negative woman involving extra nodal sites including ovary, breast and adrenal glands. Prognostic outcomes are generally dismal. On relapse, she received conventional as well as novel therapies and is disease free now, two years post allogenic haploidentical transplantation.

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

“…Hamadani and Devine achieved CR in a HIV + PBL patient[45]. As reported earlier by Kathrotiya et al, the patient has been disease-free for almost 3 years after undergoing haploidentical alloSCT[34]. Rong et al achieved complete remission in a HIV-negative and EBVnegative patient for 4 years after salvage alloSCT[46].…”

“…e patient underwent therapy with daratumumab and CHOP with only a transient response, thus unable to proceed to allogenic stem cell transplant (alloSCT) [33]. e fourth case presents a female with HIV-negative disease who received multiple lines of treatment (daEPOCH, ASCT, and DHAP) before achieving CR with bortezomib, lenalidomide, and daratumumab and eventually proceeding to alloSCT with a prolonged disease-free period [34]. Raychaudhuri et al were unable to induce remission with salvage carfilzomib and DRD in a HIV-negative and EBV-negative patient, eventually proceeding to CAR-T therapy [25].…”

Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma

“…One case report evaluated daratumumab with bortezomib and lenalidomide in the relapsed setting. 6 This patient achieved a PR followed by allogeneic stem cell transplant. A prospective trial evaluating this regimen is currently active (NCT04915248).…”